Tecogalan sodium
Alternative Names: DS 4152; SP PG; SP PG LMLatest Information Update: 03 Nov 1999
At a glance
- Originator Daiichi Pharmaceutical
- Developer Daiichi Pharmaceutical; National Cancer Institute (USA)
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections; Kaposi's sarcoma; Solid tumours
Most Recent Events
- 03 Nov 1999 Discontinued-I for Kaposi's sarcoma in European Union (Unknown route)
- 01 Oct 1998 Discontinued-I for Solid tumours in European Union (Unknown route)
- 01 Oct 1998 Discontinued-Preclinical for HIV infections treatment in Japan (Unknown route)